HEPA
Neutral signalScored 2026-09-06 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Hepion Pharmaceuticals, Inc.
- Nom
- Hepion Pharmaceuticals, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- OTC
- Capitalisation
- $1.6M
- Employés
- 2
- PDG
- Sireesh Appajosyula
- Site web
- https://www.hepionpharma.com
- Marché
- CDTCOCHENVBLIXTNIVFPTPI
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 6500000 titres (~390000 USD)
- Insiders
- Appajosyula SireeshPurcell Michael J.Stetz Gary S.Stetz Gary S. II
- Total bought
-
$390,000
Avg buy (VWAP, 90d window) $0.06 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-03
- Last synced
-
2026-08-14 10:30:55
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-29 | Fisher Danina | Buy · P | 200,000 | $0.06 | $12,000 | Form 4 |
| 2026-08-03 | Appajosyula Sireesh | Buy · P | 2,000,000 | $0.06 | $120,000 | Form 4 |
| 2026-08-03 | Purcell Michael J. | Buy · P | 2,000,000 | $0.06 | $120,000 | Form 4 |
| 2026-08-03 | Stetz Gary S. | Buy · P | 2,000,000 | $0.06 | $120,000 | Form 4 |
| 2026-08-03 | Stetz Gary S. II | Buy · P | 500,000 | $0.06 | $30,000 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-06 Drivers: fundamentals. Moteurs : fondamentaux.
While the insider cluster buy on HEPA is a notable signal — with 6.5M shares accumulated and zero offsetting sales — the underlying fundamentals are critically impaired: zero revenue, persistent negative cash flows, and…
The first sentence of the analysis written for HEPA on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 10.25 · operating margin 0.0%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 10.254 | 0.513 | 3.306 | 7.164 | 11.875 | |
| Quick Ratio | 10.254 | 0.513 | 3.306 | 7.164 | 11.875 | |
| Solvency Ratio | -20.495 | -3.785 | -4.518 | -4.055 | -3.091 | |
| Cash Ratio | 6.106 | 0.129 | 2.795 | 6.491 | 11.131 | |
| Price To Earnings Ratio | -0.068 | -0.219 | -0.263 | -0.505 | -2.449 | |
| Price To Earnings Growth Ratio | 0.001 | 0.003 | -0.073 | -0.018 | 0.031 | |
| Forward Price To Earnings Growth Ratio | 0.001 | 0.003 | -0.073 | -0.018 | 0.031 | |
| Price To Earnings Diluted Ratio | -0.068 | -0.219 | -0.263 | -0.505 | -2.449 | |
| Price To Earnings Diluted Growth Ratio | 0.001 | 0.003 | -0.073 | -0.018 | 0.031 | |
| Price To Book Ratio | 0.212 | -1.551 | 1.767 | 0.459 | 0.862 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -0.173 | -0.159 | -0.315 | -0.654 | -2.556 | |
| Price To Operating Cash Flow Ratio | -0.173 | -0.159 | -0.315 | -0.655 | -2.566 | |
| Debt To Assets Ratio | 0.018 | 1.797 | 0.012 | 0.001 | 0.003 | |
| Debt To Equity Ratio | 0.020 | -1.556 | 0.029 | 0.001 | 0.003 | |
| Debt To Capital Ratio | 0.020 | 2.797 | 0.028 | 0.001 | 0.003 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.151 | -0.866 | 2.485 | 1.208 | 1.114 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -10.928 | -5.794 | -7.729 | -4.433 | -3.805 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.000 | 1.004 | |
| Debt Service Coverage Ratio | -47.535 | -2.873 | -5,161.061 | -4,143.292 | -3,682.948 | |
| Interest Coverage Ratio | -170.601 | -15.511 | -5,118.643 | -4,475.475 | -3,431.912 | |
| Short Term Operating Cash Flow Coverage Ratio | -60.510 | -6.281 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -60.510 | -6.281 | -195.622 | -652.090 | -98.502 | |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | -2,858.562 | -2,140.130 | -239.442 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | -2,858.562 | -2,140.130 | -239.442 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 0.324 | -0.362 | 0.035 | 0.628 | 0.334 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 10.254 | ▲9.741 | ▲3.632 |
| Quick Ratio | 10.254 | ▲9.741 | ▲3.632 |
| Solvency Ratio | -20.494 | ▼-16.709 | ▼-13.306 |
| Cash Ratio | 6.106 | ▲5.977 | ▲0.775 |
| Price To Earnings Ratio | -0.068 | ▲0.151 | ▲0.633 |
| Price To Earnings Growth Ratio | 0.001 | ▼-0.002 | ▲0.012 |
| Forward Price To Earnings Growth Ratio | 0.001 | ▼-0.002 | ▲0.012 |
| Price To Earnings Diluted Ratio | -0.068 | ▲0.151 | ▲0.633 |
| Price To Earnings Diluted Growth Ratio | 0.001 | ▼-0.002 | ▲0.012 |
| Price To Book Ratio | 0.212 | ▲1.762 | ▼-0.138 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -0.173 | ▼-0.014 | ▲0.599 |
| Price To Operating Cash Flow Ratio | -0.173 | ▼-0.014 | ▲0.601 |
| Debt To Assets Ratio | 0.018 | ▼-1.780 | ▼-0.348 |
| Debt To Equity Ratio | 0.020 | ▲1.577 | ▲0.321 |
| Debt To Capital Ratio | 0.020 | ▼-2.778 | ▼-0.550 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.151 | ▲2.017 | ▲0.133 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -10.928 | ▼-5.133 | ▼-4.390 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | ▼-0.001 |
| Debt Service Coverage Ratio | -47.535 | ▼-44.663 | ▲2560.007 |
| Interest Coverage Ratio | -170.601 | ▼-155.090 | ▲2471.827 |
| Short Term Operating Cash Flow Coverage Ratio | -60.510 | ▼-54.228 | ▼-47.151 |
| Operating Cash Flow Coverage Ratio | -60.510 | ▼-54.228 | ▲142.091 |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | ▲1047.627 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | ▲1047.627 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 0.324 | ▲0.686 | ▲0.132 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $565K | $2.9M | $12.9M | $22.9M | $80.1M | |
| Enterprise value | -$1.2M | $5.4M | -$1.7M | -$28.2M | -$10.9M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | 0.37x | -0.29x | 0.04x | 0.81x | 0.35x | |
| EV / Free cash flow | 0.37x | -0.29x | 0.04x | 0.81x | 0.35x | |
| EV / EBITDA | 0.32x | -0.36x | 0.04x | 0.63x | 0.33x | |
| Net debt / EBITDA | 0.48x | -0.17x | 0.30x | 1.14x | 2.79x | |
| Current ratio | 10.25x | 0.51x | 3.31x | 7.16x | 11.88x | |
| Income quality | 0.40x | 1.38x | 0.84x | 0.83x | 0.95x | |
| Graham net-net | $0 | -$25 | $50 | $535 | $1K | |
| Tax burden | 100.0% | 81.6% | 99.2% | 93.6% | 100.0% | |
| Interest burden | 220.1% | 108.4% | 100.0% | 100.0% | 100.0% | |
| Working capital | $2.8M | -$1.5M | $12.2M | $48.6M | $89.2M | |
| Invested capital | $2.8M | -$1.5M | $12.4M | $55.1M | $94.8M | |
| Return on assets | -269.6% | -817.5% | -270.4% | -70.0% | -31.6% | |
| Operating ROA | -177.8% | -196.3% | -123.7% | -55.5% | -40.0% | |
| Return on tangible assets | -269.6% | -817.5% | -270.4% | -74.0% | -33.2% | |
| Return on equity | -310.3% | 708.0% | -672.0% | -84.6% | -35.2% | |
| Return on invested capital | -147.4% | -1152.8% | -371.9% | -81.2% | -31.8% | |
| Return on capital employed | -150.3% | 1264.4% | -378.4% | -86.9% | -31.9% | |
| Earnings yield | -1466.2% | -456.6% | -380.3% | -184.3% | -40.8% | |
| Free cash flow yield | -579.5% | -630.5% | -317.9% | -152.8% | -39.1% | |
| Capex / Op. cash flow | 0.0% | 0.0% | -0.0% | -0.0% | -0.4% | |
| Capex / Depreciation | 0.0% | 0.0% | 21.3% | 21.1% | 151.5% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 5.3% | 4.9% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- No news synced yet.